Pharmacogenetic Testing: Medication Response, Gene Variants, and Results

Pharmacogenetic testing examines inherited DNA variants that can influence how a person processes or responds to certain medicines. A useful result may help a clinician choose a drug, adjust a starting dose, avoid a serious adverse reaction, or plan closer monitoring. It does not predict every side effect, guarantee that a medicine will work, or replace clinical factors such as age, kidney and liver function, other medications, diagnosis, and treatment goals.

The most valuable test is tied to a specific prescribing decision and supported by a recognized guideline or drug label. Results often translate a genotype into a functional category such as poor, intermediate, normal, rapid, or ultrarapid metabolizer. That category is gene specific: being a CYP2C19 poor metabolizer says nothing about CYP2D6 unless both genes were tested. Because inherited results usually remain relevant for life, patients should keep the complete laboratory report and make it available whenever a new medication is considered.

• Pharmacogenetic testing can guide selected drugs, but many medicines have no validated gene-based prescribing recommendation.
• A “normal metabolizer” result does not mean every medication will be safe or effective.
• Testing is most urgent when a gene result can prevent severe toxicity, such as HLA-associated hypersensitivity or DPYD-related fluoropyrimidine toxicity.
• Drug interactions can temporarily change the expected phenotype, a situation called phenoconversion.
• A panel result should be interpreted drug by drug; one gene may affect several medicines in different ways.
• Never stop, start, or change a prescription based only on a consumer report without speaking with the prescriber or pharmacist.

Table of Contents

• What Pharmacogenetic Testing Measures
• When Testing Can Help
• Important Gene–Drug Examples
• How Results Are Reported
• Limits and Common Misunderstandings
• Choosing a Test and Laboratory
• Using Results Safely Over Time

What Pharmacogenetic Testing Measures

Pharmacogenetics focuses on how variants in one or more genes affect medication response. Pharmacogenomics is often used for broader, multi-gene approaches, but the terms overlap in clinical practice. Most tests analyze germline DNA—the inherited DNA present in nearly every cell—using blood or saliva. The result usually does not change during a person’s life.

Genes can affect medication use through several mechanisms:

• Drug metabolism: Enzymes chemically change a drug so the body can activate, inactivate, or eliminate it. CYP2D6, CYP2C19, CYP2C9, DPYD, TPMT, and NUDT15 are common examples.
• Drug transport: Proteins move drugs into, through, or out of cells. SLCO1B1 can influence statin exposure in muscle.
• Drug targets: Variants can alter the protein a medicine acts on, changing expected benefit or dose needs.
• Immune recognition: Certain HLA variants increase the risk of severe immune-mediated reactions to specific drugs.
• Cellular sensitivity: Variants in genes such as RYR1 can increase susceptibility to a dangerous response under particular anesthetic exposures.

A laboratory may test a single gene before one prescription, a small focused panel, or a larger preemptive panel intended for future use. The test can examine named variants, entire coding regions, copy-number changes, or combinations called haplotypes. The design matters because pharmacogenes can be technically difficult. CYP2D6, for example, has deletions, duplications, hybrid genes, and closely related sequences; a limited assay may assign the wrong functional category or miss an uncommon allele.

Many pharmacogenetic results use star-allele nomenclature. A result such as CYP2C19 1/2 indicates one allele with normal function and one with no function. The laboratory translates the pair, called a diplotype, into a predicted phenotype. For CYP2C19, that combination is generally an intermediate metabolizer. Different genes use different rules, and the same star number has no meaning across genes.

Some tests report an activity score, especially for CYP2D6. Each allele receives a value based on expected function, and the two values are combined. Guideline groups then map the score to a metabolizer phenotype. Because allele-function assignments and translation systems can be updated, the raw genotype and date of interpretation should remain available.

Pharmacogenetic testing is distinct from tumor genomic testing. A cancer biopsy may identify mutations that predict whether a targeted therapy will work against that tumor. Germline pharmacogenetics predicts how the patient may handle a medicine. Oncology care sometimes uses both, but they answer different questions. The principles of germline genetic testing apply to inherited pharmacogenetic findings, including the possibility of implications for relatives.

When Testing Can Help

Testing is most useful when four conditions align: a relevant drug is being considered, the gene–drug association is well supported, the result can change management, and the result will return before the prescribing decision.

Reactive testing before or during treatment

Reactive testing occurs when a clinician orders a result for a specific medication. Examples include HLA-B*57:01 before abacavir, DPYD before fluoropyrimidine chemotherapy, TPMT and NUDT15 before thiopurines, or CYP2C19 when choosing antiplatelet therapy after a coronary intervention. This approach is focused and easier to interpret, but turnaround time can be a barrier when treatment must begin immediately.

Testing can also be ordered after an unexpected response, such as severe toxicity at a standard dose, repeated failure of drugs metabolized by the same enzyme, or an unusual concentration on therapeutic drug monitoring. A result may explain part of the event, but clinicians still investigate dosing errors, interactions, organ dysfunction, adherence, and other causes.

Preemptive testing

Preemptive testing analyzes several pharmacogenes before a specific need arises and stores the results for future prescribing. Its main advantage is availability at the moment of care. Its weakness is that a broad panel may include low-evidence associations or results that never become relevant. Preemptive testing works best when the health record can deliver current, drug-specific decision support rather than leaving a static PDF to be interpreted years later.

People who take many medicines, have repeated adverse reactions, receive care in systems with pharmacogenomic decision support, or are likely to need high-impact drugs may gain more from a panel. Still, testing every person for every gene is not automatically cost-effective or clinically necessary.

Situations in which testing may add little

Testing may not help when:

• the medication has no validated genetic association;
• the result would not change the chosen drug, dose, or monitoring;
• treatment cannot wait and no rapid assay is available;
• a reliable clinical alternative already answers the question more directly;
• the person has already tolerated a stable regimen and the result would not alter care;
• the panel does not include the relevant ancestry-associated or rare variants; or
• the report uses a proprietary recommendation without transparent evidence.

A medication history often matters as much as DNA. Prior response, adverse effects, dose, treatment duration, adherence, and concurrent drugs provide real-world evidence. Pharmacogenetics should sharpen that history, not erase it.

Professional resources serve different roles. The Clinical Pharmacogenetics Implementation Consortium, or CPIC, generally answers how to use an existing genotype when prescribing. It does not necessarily recommend that everyone be tested. Drug regulators may include pharmacogenomic information in labeling or tables, but the strength and required action vary. Specialty societies may issue recommendations for a particular disease or treatment setting. A prescriber should use the source that fits the clinical context and check for updates.

Important Gene–Drug Examples

The following examples show why a result cannot be reduced to “good” or “bad genetics.” Each gene changes a specific drug decision.

Gene	Example drugs	Possible clinical concern	Typical use of result
CYP2C19	Clopidogrel, selected proton-pump inhibitors, some antidepressants	Reduced or increased metabolism depending on drug and phenotype	Choose an alternative, adjust dose, or monitor according to drug-specific guidance
CYP2D6	Codeine, tramadol, tamoxifen, atomoxetine, several antidepressants and antipsychotics	Too little active metabolite, excessive active metabolite, or altered parent-drug exposure	Avoid selected drugs or modify treatment based on phenotype and indication
DPYD	Fluorouracil, capecitabine	Reduced breakdown can cause severe or fatal toxicity	Reduce starting dose substantially or avoid treatment in severe deficiency
TPMT and NUDT15	Azathioprine, mercaptopurine, thioguanine	Marked bone-marrow toxicity at standard doses	Use lower starting doses or alternative therapy, with blood-count monitoring
HLA-B	Abacavir, allopurinol, carbamazepine	Drug-specific severe hypersensitivity or skin reactions	Avoid the implicated drug when the relevant allele is present
SLCO1B1	Simvastatin and selected other statins	Higher systemic exposure and muscle toxicity risk	Select a statin or dose with lower risk while considering cardiovascular goals
CYP2C9 and VKORC1	Warfarin	Lower or higher dose requirement and bleeding risk during initiation	Incorporate genotype into a dosing algorithm with clinical factors and INR
MT-RNR1	Aminoglycoside antibiotics	Greatly increased risk of hearing loss with certain variants	Avoid aminoglycosides when alternatives are suitable; emergency treatment may require individualized judgment

CYP2C19 and clopidogrel

Clopidogrel is a prodrug that needs metabolic activation, including through CYP2C19. Intermediate and poor metabolizers produce less active drug and may have reduced antiplatelet effect. In high-risk settings such as acute coronary syndrome or percutaneous coronary intervention, guidelines may recommend an alternative antiplatelet not dependent on CYP2C19, provided there is no contraindication. The same phenotype does not mean every CYP2C19 substrate should be avoided; proton-pump inhibitors and antidepressants have different exposure patterns and recommendations.

CYP2D6 and codeine

Codeine relies on CYP2D6 to form morphine. Poor metabolizers may receive little pain relief, while ultrarapid metabolizers can produce morphine quickly and face toxicity. Age, breastfeeding, respiratory risk, and regulatory restrictions also matter. A test result should never be used to justify codeine when the drug is otherwise inappropriate.

CYP2D6 illustrates phenoconversion. A person genetically predicted to be a normal metabolizer may function like a poor metabolizer while taking a strong CYP2D6 inhibitor. The genotype stays the same; the medication environment changes the observed enzyme activity.

DPYD and fluoropyrimidines

DPYD encodes the main enzyme that breaks down fluorouracil. Certain no-function or decreased-function variants increase exposure and the risk of severe diarrhea, mouth inflammation, low blood counts, neurologic toxicity, and death. Genotype-guided dose reduction can lower risk, but a negative targeted test does not exclude deficiency because many rare variants and nongenetic factors can affect enzyme function. Clinicians still monitor every patient closely.

HLA-associated reactions

HLA tests often produce a present-or-absent result rather than a metabolizer phenotype. HLA-B57:01 strongly predicts abacavir hypersensitivity; patients who test positive should not receive abacavir, and anyone with a clinically suspected abacavir hypersensitivity reaction should not be rechallenged regardless of the original result. HLA-B58:01 increases risk of severe allopurinol reactions. HLA-B15:02 and HLA-A31:01 can affect carbamazepine decisions, with allele frequency and recommendations varying by ancestry and population.

These are risk markers, not general allergy tests. A negative result for one allele does not prove that a person cannot have another allergic or adverse reaction to the drug.

How Results Are Reported

A complete report should show the gene, tested variants or alleles, genotype or diplotype, predicted phenotype, assay limitations, and a medication-specific interpretation. The phenotype is usually the easiest part to use, but the underlying genotype preserves information when guidelines change.

Common metabolizer categories include:

• Poor metabolizer: little or no enzyme function.
• Intermediate metabolizer: reduced function.
• Normal metabolizer: expected function based on the tested alleles.
• Rapid metabolizer: function above the reference range for certain genes.
• Ultrarapid metabolizer: substantially increased function, often from increased-function alleles or gene duplication.

Not every gene uses all categories. Transporter and immune genes may use terms such as decreased function, increased risk, positive, negative, susceptible, or indeterminate.

“Normal” means expected activity for that gene and translation system, not that the person has no variants. It also does not mean a standard dose will be ideal. Kidney function, liver function, body size, age, pregnancy, inflammation, smoking, diet, adherence, and drug interactions can outweigh or modify the genetic effect.

An indeterminate result can arise when the laboratory cannot assign function to the observed allele combination, detects a variant not covered by current translation rules, or cannot resolve gene structure. This is different from a variant of uncertain significance in a disease-diagnostic test, though both signal uncertainty. Pharmacogenetic reports often restrict themselves to established star alleles and may not report unrelated disease risks.

Some direct-to-consumer reports list individual variants without testing the full gene. A negative result then means only that the selected variants were absent. For a gene with many rare functional alleles, that can create false reassurance. Clinical confirmation is appropriate before a high-stakes prescribing change.

A multi-gene panel may produce a long medication list. Read it in layers:

1. Identify which current or likely future medicines have a strong, actionable association.
2. Match each drug to the correct gene and phenotype.
3. Check the recommendation’s evidence source and date.
4. Add current clinical factors and interactions.
5. Decide whether to change therapy, adjust dose, monitor differently, or take no action.

A red or yellow color on a commercial dashboard is not a universal medical classification. Laboratories use different color systems and proprietary algorithms. The written recommendation and evidence source are more important than the visual warning.

Limits and Common Misunderstandings

Pharmacogenetic testing explains only part of medication variability. Even a well-established gene may account for a modest fraction of response, and many adverse effects arise through mechanisms unrelated to the tested pathway.

A result does not choose the “best” medication by itself

The best treatment depends on diagnosis, comparative effectiveness, contraindications, prior response, patient preference, cost, access, and monitoring. A favorable genotype cannot make an ineffective drug appropriate for the condition. An unfavorable genotype may sometimes be managed with dose adjustment rather than avoidance.

Panel breadth is not the same as quality

A panel with dozens of genes may look comprehensive but mix high-evidence pairs with associations that lack prescribing guidance. More results can create more noise. A focused, well-validated assay may be more useful for an immediate decision.

Tested variants differ across ancestry groups

Allele frequencies vary across populations, and historical studies have not represented all ancestry groups equally. A panel designed around common European variants may miss important alleles in people with African, Asian, Indigenous, Middle Eastern, or admixed ancestry. Ancestry should not be used as a crude substitute for testing, but it should prompt evaluation of whether the assay has adequate coverage.

Drug–drug interactions can override genotype

Enzyme inhibitors can reduce activity; inducers can increase it. Inflammation can also suppress some metabolic pathways. The resulting phenotype at a given moment may differ from the inherited prediction. Medication reconciliation is therefore essential each time a result is used.

Results may have implications beyond prescribing

Most pharmacogenetic variants do not diagnose disease. However, broader sequencing or certain genes can reveal information with family or health implications. For example, some RYR1 findings relate to malignant hyperthermia susceptibility, and selected G6PD findings may have significance beyond one medicine. Consent and reporting policy should clarify whether such findings are included.

Evidence sources can disagree

CPIC, regulatory labeling, and specialty guidelines may differ because they ask different questions, review evidence at different times, or apply recommendations to different populations. A discrepancy does not automatically mean one source is wrong. The clinician should document which recommendation was used and why.

A negative test is bounded by assay coverage

A negative result does not mean the gene functions normally unless the assay could detect the relevant alleles and structural changes. Ask whether the laboratory reports residual risk, copy number, rare alleles, and technical limitations.

Choosing a Test and Laboratory

Start with the medication decision, not the largest available panel. Ask the prescriber or pharmacist which gene–drug pair is relevant and whether the result would change care. Then evaluate whether the test can answer that question before treatment begins.

A strong clinical test should provide:

• validation in an appropriately regulated clinical laboratory;
• transparent allele and variant coverage;
• copy-number or structural analysis when required for the gene;
• clear genotype-to-phenotype translation;
• drug-specific recommendations tied to recognized evidence;
• limitations for rare alleles and ancestry representation;
• a policy for updated interpretation; and
• access to a clinician, pharmacist, or genetics professional who can explain the result.

Turnaround can range from hours for a rapid single-gene test to several days or weeks for a panel. An emergency drug decision may need a non-genetic alternative. Cost and insurance coverage vary by indication, laboratory, and health plan. Before testing, ask about the total price, confirmatory testing, counseling, and whether the result will be integrated into the electronic health record.

Saliva and blood usually provide equivalent inherited DNA, but sample quality can affect failure rates. Bone marrow transplant recipients, people with certain blood cancers, and recent transfusion recipients may require special consideration because blood-derived DNA may not reflect the person’s original germline in the usual way. The laboratory should advise on the correct specimen.

Review the test’s scope before consent. Some panels report only medication guidance. Others may identify disease-associated variants, carrier findings, or ancestry information. A report limited to a preselected set of common pharmacogenetic variants should not be mistaken for whole-genome sequencing.

For mental health care, be cautious with combinatorial commercial panels that rank antidepressants into color categories using proprietary algorithms. Individual gene–drug relationships may be useful, but evidence for a bundled prediction of overall medication success can be uneven. The test should complement a full psychiatric assessment and careful medication trial, not replace them.

Using Results Safely Over Time

A pharmacogenetic result can remain relevant for decades, but its interpretation may change. Keep the original laboratory report, not just a wallet card or screenshot. The report should include the exact genotype, tested method, date, and laboratory.

Share the result with the prescribing clinician and pharmacist whenever a relevant medicine is considered. Ask for structured entry into the health record so decision-support systems can recognize it. A PDF buried under scanned documents may not trigger an alert.

Before changing treatment, the clinician should confirm:

• the result belongs to the correct person and came from a clinical-grade test;
• the drug is actually affected by the reported gene;
• the current guideline applies to the indication and population;
• interacting medicines have been reviewed;
• organ function and other clinical factors are current;
• the recommended alternative is appropriate; and
• monitoring is arranged.

Do not stop medications abruptly. Antidepressants, antiseizure drugs, steroids, beta blockers, anticoagulants, and many other therapies can cause harm if discontinued without a plan. A result found years after successful treatment does not always require a change; benefit, tolerance, and risk of switching matter.

Reinterpretation is especially important when an old test used limited coverage or when allele-function assignments have changed. Rather than repeating the entire panel automatically, ask whether the laboratory can update the phenotype from the existing genotype. Repeat testing may be useful if the original assay omitted structural variants or relevant alleles.

Relatives may share pharmacogenetic alleles, but one person’s result should not be copied into another person’s chart. Each relative needs their own validated test when the result would affect prescribing. A family history of a severe drug reaction can still guide avoidance while testing is arranged.

Use urgent care for signs of a severe drug reaction, including trouble breathing, swelling of the face or throat, widespread blistering or peeling rash, fainting, severe confusion, uncontrolled bleeding, high fever with rash, or rapidly worsening weakness. Pharmacogenetic testing is preventive information; it is not an emergency diagnostic tool once a serious reaction has started.

The safest use of pharmacogenetics is precise and limited: the right result, applied to the right drug, at the right time, with current clinical information. It can meaningfully reduce risk and improve dosing for selected therapies, but it works as part of medication management—not as an automated prescription generator.

References

• CPIC Guidelines 2026 (Guideline)
• Table of Pharmacogenetic Associations 2022
• Table of Pharmacogenomic Biomarkers in Drug Labeling 2026
• Implementation of pharmacogenomics testing for precision medicine: A review of current barriers and solutions 2024 (Review)
• Pharmacogenomics in practice: a review and implementation guide 2023 (Review)
• Scoping review of enablers and challenges of implementing pharmacogenomics in routine clinical practice 2024 (Review)

Disclaimer

This article is educational and is not a medication recommendation or substitute for care from a prescriber, pharmacist, or genetics professional. Do not start, stop, or change a drug or dose based on a pharmacogenetic result without clinical review. Seek emergency care for breathing difficulty, facial swelling, blistering rash, severe bleeding, collapse, or another serious drug reaction.